Celldex Therapeutics, Inc. company, formerly known as AVANT Immunotherapeutics, Inc., was founded in 1983 and is headquartered in Needham, Massachusetts. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases. The company focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through targeted immunization approach. It also offers bacterial vector delivery technologies with manufacturing and preservation processes that offer the potential for a new generation of infectious disease vaccines.Celldex Company's products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines.

GlaxoSmithKline S.p.A. (GSK Italy), the Italian unit of global pharmaceutical giant GlaxoSmithKline. GSK Italy promotes and sells the therapeutic products of its parent company in the Italian market. The company also makes antibiotics, vaccines, and other injectable drugs at its manufacturing facilities in Parma and Verona, and it has a Milan-based division that sells consumer health care products and over-the-counter drugs. In addition, GSK Italy boasts a research and development unit in Verona that targets neurological drug development, including treatments for depression, addiction, schizophrenia, and sleep disorders.

Helix BioPharma discovers, develops, and seeks licensing for pharmaceuticals to prevent and treat cancer. The company's drug candidates include treatments for female conditions such as human papillomavirus (HPV), a precursor to cervical cancer; common forms of lung cancer such as andenocarcinoma; and potential therapies for breast and prostate cancers. To help fund its drug discovery operations, Helix BioPharma distributes pharmaceuticals and other products for conditions such as gastrointestinal, orthopedic, and immune system disorders in Canada through subsidiary Rivex Pharma.

Oncothyreon Inc. was founded in 1985 and is headquartered in Bellevue, Washington. Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon’s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company’s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

BioMarin Pharmaceutical Inc. company was founded in 1996 and is headquartered in Novato, California. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase.Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation.

Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania. Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan’s products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA’s Central & Eastern Europe (CEE) generics businesses.

Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.

AstraZeneca was founded in 1992 and is headquartered in London, the United Kingdom. AstraZeneca plc (LSE: AZN) operates independently of Imperial Chemical Industries plc as of June 1, 1993. AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients.AstraZeneca company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; Mental Health Research Institute; Targacept, Inc.; and Dako Denmark A/S. AstraZeneca also has a drug discovery and development agreement with PsychoGenics Inc. to identify compounds that are useful for the treatment of certain central nervous system disorders.

Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.

New Energy Technologies, Inc. was founded in 1998 and is based in Burtonsville, Maryland. New Energy Technologies, Inc., through its subsidiaries, engages in the identification, acquisition, development, and commercialization of alternative energy technologies. It focuses on the development of MotionPower, a technology for capturing the kinetic energy of moving vehicles in order to use this captured energy to generate electricity; and SolarWindow, a technology that enables transparent glass windows to generate electricity by coating their glass surfaces with small solar cells. The company was formerly known as Octillion Corp. and changed its name to New Energy Technologies, Inc. in January 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.